Therapeutic drug monitoring and the therapeutic reference range of Levetiracetam for Chinese patients: problems and issues

Epilepsy is a chronic neurological disease and the single most common brain disorder worldwide. It affects individuals of all ages, races, social status, and nations. More than 70 million people have been diagnosed with epilepsy worldwide and nearly 90% of them live in developing regions [1,2]. Approximately, 9 million patients with epilepsy have been reported in China accounting for nearly 20% of the cases worldwide, with an annual growth rate of 40,000 [3]. Antiseizure drugs are the cornerstone of epilepsy treatment.

0